Journal of Gynecologic Oncology最新文献

{"title":"Efficacy and toxicity of PARP inhibitor in elderly patients with homologous recombination-deficient newly diagnosed advanced ovarian cancer: the role of dose modification.","authors":"Ji Hyun Kim, Dongkyu Eugene Kim, Uisuk Kim, Jae Kyung Bae, Wan Hu Jin, Sang-Yoon Park, Myong Cheol Lim","doi":"10.3802/jgo.2026.37.e9","DOIUrl":"https://doi.org/10.3802/jgo.2026.37.e9","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the impact of age on the progression-free survival (PFS) and dose modification, discontinuation and adverse events of poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) maintenance therapy in homologous recombination-deficient (HRD) ovarian cancer patients.</p><p><strong>Methods: </strong>We analyzed 324 patients with advanced stage III-IV epithelial ovarian cancer who had either BRCA mutation or HRD between July 2019 and November 2022. The primary objective was to evaluate the efficacy of PARPis by comparing PFS between patients who received PARPis and those who did not, specifically within 2 age groups: patients aged <60 years and those aged ≥60 years. The secondary objective included evaluating the rates of dose modification, discontinuation, and occurrence of treatment-emergent adverse events in patients who used PARPis.</p><p><strong>Results: </strong>Of the 324 patients, 139 patients (42.9%) were diagnosed at ≥60 years. The use of PARPis resulted in a significant improvement in PFS in both age groups (hazard ratio [HR]=0.37; p<0.01) for patients aged <60 years (HR=0.41; p<0.01) for those aged ≥60 years. The multivariable Cox proportional hazards analysis revealed no significant difference in the PFS benefit between the 2 age groups (HR=0.95; 95% confidence interval [CI]=0.65-1.37; p=0.76). Dose modifications were more frequent in the elderly cohort (63.9% vs. 46.5%; p=0.04).</p><p><strong>Conclusion: </strong>PARPis significantly improved PFS in elderly ovarian cancer patients with BRCA mutations and HRD, with a toxicity profile similar to that of younger patients. Elderly patients benefited from frequent dose modifications without any negative impact on PFS outcomes.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to editor regarding the published manuscript: \"A prospective comparison of the diagnostic accuracies of ultrasound and magnetic resonance imaging in preoperative staging of endometrial cancer\".","authors":"Erik Rud, Kristina Galtung Flor, Peter Mærhre Lauritzen","doi":"10.3802/jgo.2025.36.e134","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e134","url":null,"abstract":"","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 2nd Annual Meeting of the East Asian Gynecologic Oncology Trial Group (EAGOT).","authors":"Shin-Wha Lee, So Hyun Nam, Chyong-Huey Lai, Xiaohua Wu, Aikou Okamoto, Jae-Hoon Kim, Takayuki Enomoto, Yong Man Kim","doi":"10.3802/jgo.2025.36.e135","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e135","url":null,"abstract":"","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FUS-stabilized USP7 facilitates the bevacizumab resistance of ovarian cancer through deubiquitinating PTK2.","authors":"Xianping Wen, Ruocheng Xu, Ranran Li, Shuo Li, Guantai Ni","doi":"10.3802/jgo.2026.37.e3","DOIUrl":"https://doi.org/10.3802/jgo.2026.37.e3","url":null,"abstract":"<p><strong>Objective: </strong>The emergence of drug resistance brings new challenges to the clinical management of ovarian cancer (OC) patients. This study aimed to explore the role and mechanism of ubiquitin-specific peptidase 7 (USP7) on the bevacizumab resistance of OC.</p><p><strong>Methods: </strong>The mRNA levels of USP7 and protein tyrosine kinase 2 (PTK2) were measured using quantitative real-time polymerase chain reaction. Western blot analysis was used for detecting the protein levels of USP7, PTK2 and fused in sarcoma (FUS). Cell resistance, proliferation, apoptosis, invasion and angiogenesis were determined by cell counting kit 8 assay, colony formation assay, flow cytometry, transwell assay and tube formation assay. Glucose consumption, lactate production, and ATP/ADP ratio were used to evaluate glycolysis. The interactions between USP7 and PTK2/FUS were detected by co-immunoprecipitation assay. Mice xenograft model was also constructed to explore USP7 roles in vivo.</p><p><strong>Results: </strong>USP7 was upregulated in OC tissues and bevacizumab-resistant cells. USP7 knockdown or its inhibitor P22077 inhibited the bevacizumab resistance of OC cells via suppressing cell growth, metastasis, angiogenesis and glycolysis. USP7 stabilized PTK2 protein expression via deubiquitinating. PTK2 overexpression reversed the effect of USP7 knockdown on the bevacizumab resistance of OC cells. Besides, FUS stabilized USP7 mRNA to regulate its protein level, and it could affect PTK2 expression by mediating USP7. USP7 knockdown enhanced the sensitivity of OC tumors to bevacizumab in vivo.</p><p><strong>Conclusion: </strong>FUS-stabilized USP7 enhanced the bevacizumab resistance of OC by deubiquitinating PTK2, providing a new idea for overcoming bevacizumab resistance in OC.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical analysis of the impact of systematic pelvic and para-aortic lymphadenectomy on the prognosis of patients with early-stage ovarian cancer (stage IA-IIA): a propensity score matching study.","authors":"Siyuan Zeng, Simin Xiao, Mingzhu Jia, Zhao Hu, Lin Changsheng, Lei Yu, Huiling Chen, Xue Xiao","doi":"10.3802/jgo.2026.37.e5","DOIUrl":"https://doi.org/10.3802/jgo.2026.37.e5","url":null,"abstract":"<p><strong>Objective: </strong>The role of systematic pelvic and para-aortic lymphadenectomy (PPAL) in completion staging surgery for early-stage (stage I-IIA) ovarian cancer (EOC) remains controversial. This study evaluates the impact of PPAL on the prognosis of EOC patients.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted using data from the Surveillance, Epidemiology, and End Results database. Patients with EOC (stage I-IIA) were included. Propensity score matching (PSM) was used at a 1:1 ratio based on age, marital status, race, tumor grade, histological type, FIGO stage, and postoperative adjuvant therapy. Post-matching overall survival (OS) and cancer-specific survival (CSS) were compared between the systematic PPAL group (pathological staging) and the non-lymphadenectomy group (clinical staging).</p><p><strong>Results: </strong>After PSM, no significant differences were observed in OS (p=0.140) and CSS (p=0.066) between the two groups. Subgroup analysis showed that for tumor grade III patients, the pathological staging group had significantly higher OS (p=0.028) and CSS (p=0.010) than the clinical staging group. Multivariate Cox regression indicated that tumor grade III was an independent prognostic factor for OS (p=0.006) and CSS (p=0.020).</p><p><strong>Conclusion: </strong>Systematic PPAL does not significantly improve survival in EOC patients. However, for tumor grade III patients, the pathological staging group demonstrates significantly better prognosis, offering a more personalized alternative to routine staging surgery, which requires further validation through prospective trials.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genotype distribution and risk factors for human papillomavirus infection.","authors":"Yanqing Shen, Zuwei Zhang, Shaole Shi, Caixia Zhang, Channi Wang, Ye Chen","doi":"10.3802/jgo.2026.37.e7","DOIUrl":"https://doi.org/10.3802/jgo.2026.37.e7","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the patterns of human papillomavirus (HPV) genotype distribution and identify high-risk factors for HPV infection, focusing on their etiological significance and potential public health implications.</p><p><strong>Methods: </strong>This study enrolled 496 women from the Gynecology Outpatient Department of Wuhan Central Hospital between September 2021 and September 2024. Data were collected through medical records and questionnaire surveys to analyze the distribution characteristics of HPV infection. High-risk factors were evaluated using multivariate binary logistic regression analysis.</p><p><strong>Results: </strong>HPV infection exhibited the highest infection rate among women ≤25 years (63.5%) and ≥49 years (55.0%), with the most common types of high-risk HPV being HPV52, 16, and 58. Protective factors included frequent condom use (odds ratio [OR]=0.580) and HPV vaccination (OR=0.564). High-risk factors included diabetes (OR=6.620), anxiety (OR=2.126), and low work intensity (OR=1.670).</p><p><strong>Conclusion: </strong>This study demonstrated diabetes, anxiety, and low work intensity as significant risk factors for HPV infection, providing valuable etiological insights. Psychological assessments and diabetes management should be integrated into public health strategies for HPV prevention. Furthermore, multidisciplinary collaboration among gynecologists, psychologists, and endocrinologists, is also recommended to prevention and care efforts.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and biological characteristics associated with of loss-of-heterozygosity in endometrial cancer.","authors":"Felix Blanc-Durand, Etienne Rouleau, Patricia Pautier, Natalie Ngoi, Yi Wan Lim, Siew Eng Lim, Alexandra Leary, David Sp Tan","doi":"10.3802/jgo.2026.37.e10","DOIUrl":"https://doi.org/10.3802/jgo.2026.37.e10","url":null,"abstract":"<p><strong>Objective: </strong>Genomic instability has been identified in a subgroup of endometrial cancers (ECs) that are predominantly <i>TP53</i> mutated (<i>TP53mut</i>). We report the features associated with loss-of-heterozygosity (LOH) in EC.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of EC patients from France and Singapore. All patients underwent comprehensive molecular profiling using the tumor based FoundationOne CDX panel. The degree of LOH was correlated with molecular and clinicopathologic findings. LOH-high, intermediate and low were defined as ≥14%, 4%-14%, and <4%, respectively.</p><p><strong>Results: </strong>One hundred twelve patients were identified, including 66% Asian and 34% Caucasian. Fifty nine percent had International Federation of Gynecology and Obstetrics III/IV diseases, 34% low-grade endometrioid, 19% high-grade endometrioid, and 15% serous. The 63% and 50% of tumors expressed estrogen receptor (ER) and progesterone receptor (PR). One percent had a <i>POLE</i> mutation, 18% were microsatellite instability (MSI)-, 40% <i>TP53mut</i> and 41% non-specific molecular profiles. The 17% of patients were classified LOH-high, 37% LOH-intermediate and 46% LOH-low. LOH-high was significantly associated with serous and carcinosarcomas, ER/PR negative tumors, <i>TP53</i> mutations, <i>BRCA1</i> mutations and <i>TERC</i> amplification whereas LOH-low with low-grade endometrioid, MSI, <i>ARID1A</i>, <i>PIK3CA</i>, <i>CTNNB1</i>, and <i>PTEN</i> mutations. The median overall survival was 42.2, 55.2, and 100.8 months in the LOH-high, intermediate, and low respectively (p=0.034). Among <i>TP53mut</i> EC, LOH-low patients had significantly poorer outcomes (p<0.001).</p><p><strong>Conclusion: </strong>In this large multiethnic cohort, 17% of EC exhibited high LOH and correlated with hormone-receptor-negative tumors and poorer survival rates. LOH may serve as a tool for identifying EC cases with high genomic instability that could potentially benefit from PARP inhibitors.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status of carboplatin desensitization therapy for gynecologic malignancies.","authors":"Hiroshi Nishio, Koji Matsumoto, Hiroaki Komatsu, Mitsunori Morita, Takayuki Nagasawa, Jiro Suzuki, Shin Nishio, Mitsuya Ishikawa, Toyomi Satoh","doi":"10.3802/jgo.2026.37.e11","DOIUrl":"https://doi.org/10.3802/jgo.2026.37.e11","url":null,"abstract":"<p><p>Platinum-based chemotherapies are widely used in the treatment of gynecologic malignancies and are standard treatment for initial treatment and recurrent diseases. Due to the widespread use of platinum-based regimens, the management of platinum hypersensitivity reactions (HSRs) is an important issue for physicians treating gynecologic malignancies. Patients receiving multiple lines of platinum therapy, with long intervals between platinum lines and history of allergic reaction, and status of germline <i>BRCA</i> mutation are at an increased risk of platinum HSRs. The development of desensitization protocols to allow patients with platinum hypersensitivity to receive further therapy is mandatory. Each institution should work with its' multidisciplinary team to select a protocol that best suits individual practice setting and patient population to maximize patients care.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative conventional versus hypofractionated intensity-modulated radiation therapy with concurrent chemotherapy in cervical cancer: a prospective multicenter randomized phase III trial (POHIM_P3 trial).","authors":"Won Kyung Cho, Won Park, Jong Hoon Lee, Hyun-Cheol Kang, Meesun Yoon, Keun-Yong Eom, Yeon-Sil Kim, Sangjoon Park, Young Seok Kim, Yeon Joo Kim, Euncheol Choi, Dong-Yun Kim","doi":"10.3802/jgo.2026.37.e4","DOIUrl":"https://doi.org/10.3802/jgo.2026.37.e4","url":null,"abstract":"<p><strong>Background: </strong>For patients with high-risk factors such as pelvic lymph node metastasis, positive surgical margins, or parametrial involvement, concurrent chemoradiotherapy (CCRT) with whole-pelvic radiotherapy significantly improves survival outcomes. Hypofractionated radiation therapy, which delivers higher radiation doses over fewer sessions, enhances tumor control but raises concerns about increased normal tissue toxicity. A recent Korean phase II study (POHIM-CCRT) evaluated the safety of hypofractionated intensity-modulated radiation therapy (IMRT), delivering 40 Gy in 16 fractions with weekly cisplatin following radical surgery. The results showed minimal acute toxicity. Based on these findings, the present study was designed to assess the oncologic efficacy of hypofractionated CCRT compared to conventional treatment strategies in high-risk cervical cancer patients after radical surgery.</p><p><strong>Methods: </strong>The POHIM-P3 trial is a phase 3, randomized, multicenter study designed for women with cervical cancer requiring adjuvant CCRT after radical hysterectomy. Participants in the experimental arm receive hypofractionated IMRT to whole pelvis, delivering a total dose of 40 Gy in 16 fractions, and the control arm receive conventional radiotherapy with a total dose of 45-50.4 Gy in 25-28 fractions in combination with weekly cisplatin. The primary endpoint of the study is the 3-year disease-free survival and the secondary endpoints included acute and late side-effects, local control rates, and overall survival rates.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT06509724.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multimodal intervention program to improve sexual health and self-perceived quality of life in patients treated for cervical cancer: a randomized prospective study (PROVIDENCE trial).","authors":"Blanca Gil-Ibañez, Núria Carreras-Dieguez, Gregorio López, Beatriz Sánchez-Hoyo, Beatrice Conti Nuño, Reyes Oliver-Perez, Camil Castelo-Branco, Tiermes Marina, Aureli Torné, Alvaro Tejerizo, Berta Diaz-Feijoo","doi":"10.3802/jgo.2025.36.e56","DOIUrl":"10.3802/jgo.2025.36.e56","url":null,"abstract":"<p><strong>Background: </strong>Patients with cervical cancer treatment experience an impairment of sexual function and quality of life. This issue is usually underreported and undertreated, and evidence-based interventions are lacking. Prevention of sexual dysfunction is a crucial pillar in improving the quality of life of these patients. The primary objective of this trial is to evaluate the impact of a multimodal intervention, encompassing prevention of vaginal dysfunction and patient education, on sexual function and quality of life in cervical cancer survivors utilizing patient-reported outcome measurements.</p><p><strong>Methods: </strong>Multi-institutional, randomized clinical trial where patients will be randomized 1:2 at diagnosis of initial or locally advanced cervical cancer to control arm or intervention arm. After treatment, control arm patients will undergo standard follow-up by their referring physician. The multimodal intervention for patients in the intervention group includes application of vaginal estrogens plus hyaluronic-acid cream along with use of vaginal vibrator, systematic evaluation of the need of systemic hormone replacement therapy and treatment if needed, and access to online content about sexuality, nutrition, sports and lifestyle habits. Through 4 appointments (at diagnosis, 1, 6, and 12 months after treatment), sexual health, vaginal trophism and self-perceived quality of life of patients in both arms will be assessed with validated questionnaires as female sexual function index (FSFI), European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30, and Cx-24, Cervantes Scale, vaginal health index and vaginal thickness assessed by ultrasound. The major inclusion criteria will be patients aged ≥18 years with the International Federation of Gynecology and Obstetrics stage I-III cervical cancer treated with surgery and/or radiotherapy. The primary endpoint will be FSFI score 12 months after treatment, which will be compared between groups. Uni- and multivariate analysis will be performed to identify factors influencing sexual function recovery after treatment. The sample size will be of 120 eligible patients, who will be randomized to detect an improvement of 5.2 points in FSFI score. Complete accrual is estimated in March 2026. To date, the present study has no external funding.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT06031493.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e56"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}